New hope for patients with rare, relapsing organ disease
NCT ID NCT05145816
Summary
This study is testing a drug called belantamab mafodotin for people with AL amyloidosis that has come back or hasn't responded to other treatments. The goal is to find a safe and effective dose and see if it can reduce the disease in the blood and improve organ function, especially in the heart. The study will enroll up to 37 adults who have already tried standard therapies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Huntsman Cancer Institute, University of Utah
NOT_YET_RECRUITINGSalt Lake City, Utah, 84112, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UT Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Vanderbilt Ingram Cancer Center
NOT_YET_RECRUITINGNashville, Tennessee, 37232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.